Potent inhibition of human neutrophil activations by bractelactone, A novel chalcone from Fissistigma bracteolatum

Yang Chang Wu, Munisamy Sureshbabu, Yao Ching Fang, Yi Hsiu Wu, Yu Hsuan Lan, Fang Rong Chang, Ya Wen Chang, Tsong Long Hwang

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Fissistigma bracteolatum is widely used in traditional medicine to treat inflammatory diseases. However, its active components and mechanisms of action remain unclear. In this study, (3Z)-6,7-dihydroxy-4-methoxy-3-(phenylmethylidene)-5-(3-phenylpropanoyl)-1-benzofuran-2(3H) (bractelactone), a novel chalcone from F. bracteolatum, showed potent inhibitory effects against superoxide anion (O2 -) production, elastase release, and CD11b expression in formyl-l-methionyl-l-leucyl-l-phenylalanine (FMLP)-induced human neutrophils. However, bractelactone showed only weak inhibition of phorbol myristate acetate-caused O2 - production. The peak cytosolic calcium concentration ([Ca2+]i) was unaltered by bractelactone in FMLP-induced neutrophils, but the decay time of [Ca2+]i was significantly shortened. In a calcium-free solution, changes in [Ca2+]i caused by the addition of extracellular Ca2+ were inhibited by bractelactone in FMLP-activated cells. In addition, bractelactone did not alter the phosphorylation of p38 MAPK, ERK, JNK, or AKT or the concentration of cAMP. These results suggest that bractelactone selectively inhibits store-operated calcium entry (SOCE). In agreement with this concept, bractelactone suppressed sustained [Ca2+]i changes in thapsigargin-activated neutrophils. Furthermore, bractelactone did not alter FMLP-induced formation of inositol 1,4,5-triphosphate. Taken together, our results demonstrate that the anti-inflammatory effects of bractelactone, an active ingredient of F. bracteolatum, in human neutrophils are through the selective inhibition of SOCE.

Original languageEnglish
Pages (from-to)399-407
Number of pages9
JournalToxicology and Applied Pharmacology
Volume266
Issue number3
DOIs
Publication statusPublished - Feb 1 2013
Externally publishedYes

Fingerprint

leucyl-phenylalanine
Annonaceae
Chalcone
Neutrophil Activation
Phenylalanine
Neutrophils
Chemical activation
Calcium
Phosphorylation
Inositol 1,4,5-Trisphosphate
Thapsigargin
Pancreatic Elastase
Traditional Medicine
Tetradecanoylphorbol Acetate
p38 Mitogen-Activated Protein Kinases
Superoxides
Medicine
Anti-Inflammatory Agents

Keywords

  • Bractelactone
  • Calcium
  • Elastase
  • Fissistigma bracteolatum
  • Neutrophils
  • Superoxide anion

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Potent inhibition of human neutrophil activations by bractelactone, A novel chalcone from Fissistigma bracteolatum. / Wu, Yang Chang; Sureshbabu, Munisamy; Fang, Yao Ching; Wu, Yi Hsiu; Lan, Yu Hsuan; Chang, Fang Rong; Chang, Ya Wen; Hwang, Tsong Long.

In: Toxicology and Applied Pharmacology, Vol. 266, No. 3, 01.02.2013, p. 399-407.

Research output: Contribution to journalArticle

Wu, Yang Chang ; Sureshbabu, Munisamy ; Fang, Yao Ching ; Wu, Yi Hsiu ; Lan, Yu Hsuan ; Chang, Fang Rong ; Chang, Ya Wen ; Hwang, Tsong Long. / Potent inhibition of human neutrophil activations by bractelactone, A novel chalcone from Fissistigma bracteolatum. In: Toxicology and Applied Pharmacology. 2013 ; Vol. 266, No. 3. pp. 399-407.
@article{a1b8718540b94255ba61f58bda6d3f3c,
title = "Potent inhibition of human neutrophil activations by bractelactone, A novel chalcone from Fissistigma bracteolatum",
abstract = "Fissistigma bracteolatum is widely used in traditional medicine to treat inflammatory diseases. However, its active components and mechanisms of action remain unclear. In this study, (3Z)-6,7-dihydroxy-4-methoxy-3-(phenylmethylidene)-5-(3-phenylpropanoyl)-1-benzofuran-2(3H) (bractelactone), a novel chalcone from F. bracteolatum, showed potent inhibitory effects against superoxide anion (O2 -) production, elastase release, and CD11b expression in formyl-l-methionyl-l-leucyl-l-phenylalanine (FMLP)-induced human neutrophils. However, bractelactone showed only weak inhibition of phorbol myristate acetate-caused O2 - production. The peak cytosolic calcium concentration ([Ca2+]i) was unaltered by bractelactone in FMLP-induced neutrophils, but the decay time of [Ca2+]i was significantly shortened. In a calcium-free solution, changes in [Ca2+]i caused by the addition of extracellular Ca2+ were inhibited by bractelactone in FMLP-activated cells. In addition, bractelactone did not alter the phosphorylation of p38 MAPK, ERK, JNK, or AKT or the concentration of cAMP. These results suggest that bractelactone selectively inhibits store-operated calcium entry (SOCE). In agreement with this concept, bractelactone suppressed sustained [Ca2+]i changes in thapsigargin-activated neutrophils. Furthermore, bractelactone did not alter FMLP-induced formation of inositol 1,4,5-triphosphate. Taken together, our results demonstrate that the anti-inflammatory effects of bractelactone, an active ingredient of F. bracteolatum, in human neutrophils are through the selective inhibition of SOCE.",
keywords = "Bractelactone, Calcium, Elastase, Fissistigma bracteolatum, Neutrophils, Superoxide anion, Bractelactone, Calcium, Elastase, Fissistigma bracteolatum, Neutrophils, Superoxide anion",
author = "Wu, {Yang Chang} and Munisamy Sureshbabu and Fang, {Yao Ching} and Wu, {Yi Hsiu} and Lan, {Yu Hsuan} and Chang, {Fang Rong} and Chang, {Ya Wen} and Hwang, {Tsong Long}",
year = "2013",
month = "2",
day = "1",
doi = "10.1016/j.taap.2012.11.021",
language = "English",
volume = "266",
pages = "399--407",
journal = "Toxicology and Applied Pharmacology",
issn = "0041-008X",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Potent inhibition of human neutrophil activations by bractelactone, A novel chalcone from Fissistigma bracteolatum

AU - Wu, Yang Chang

AU - Sureshbabu, Munisamy

AU - Fang, Yao Ching

AU - Wu, Yi Hsiu

AU - Lan, Yu Hsuan

AU - Chang, Fang Rong

AU - Chang, Ya Wen

AU - Hwang, Tsong Long

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Fissistigma bracteolatum is widely used in traditional medicine to treat inflammatory diseases. However, its active components and mechanisms of action remain unclear. In this study, (3Z)-6,7-dihydroxy-4-methoxy-3-(phenylmethylidene)-5-(3-phenylpropanoyl)-1-benzofuran-2(3H) (bractelactone), a novel chalcone from F. bracteolatum, showed potent inhibitory effects against superoxide anion (O2 -) production, elastase release, and CD11b expression in formyl-l-methionyl-l-leucyl-l-phenylalanine (FMLP)-induced human neutrophils. However, bractelactone showed only weak inhibition of phorbol myristate acetate-caused O2 - production. The peak cytosolic calcium concentration ([Ca2+]i) was unaltered by bractelactone in FMLP-induced neutrophils, but the decay time of [Ca2+]i was significantly shortened. In a calcium-free solution, changes in [Ca2+]i caused by the addition of extracellular Ca2+ were inhibited by bractelactone in FMLP-activated cells. In addition, bractelactone did not alter the phosphorylation of p38 MAPK, ERK, JNK, or AKT or the concentration of cAMP. These results suggest that bractelactone selectively inhibits store-operated calcium entry (SOCE). In agreement with this concept, bractelactone suppressed sustained [Ca2+]i changes in thapsigargin-activated neutrophils. Furthermore, bractelactone did not alter FMLP-induced formation of inositol 1,4,5-triphosphate. Taken together, our results demonstrate that the anti-inflammatory effects of bractelactone, an active ingredient of F. bracteolatum, in human neutrophils are through the selective inhibition of SOCE.

AB - Fissistigma bracteolatum is widely used in traditional medicine to treat inflammatory diseases. However, its active components and mechanisms of action remain unclear. In this study, (3Z)-6,7-dihydroxy-4-methoxy-3-(phenylmethylidene)-5-(3-phenylpropanoyl)-1-benzofuran-2(3H) (bractelactone), a novel chalcone from F. bracteolatum, showed potent inhibitory effects against superoxide anion (O2 -) production, elastase release, and CD11b expression in formyl-l-methionyl-l-leucyl-l-phenylalanine (FMLP)-induced human neutrophils. However, bractelactone showed only weak inhibition of phorbol myristate acetate-caused O2 - production. The peak cytosolic calcium concentration ([Ca2+]i) was unaltered by bractelactone in FMLP-induced neutrophils, but the decay time of [Ca2+]i was significantly shortened. In a calcium-free solution, changes in [Ca2+]i caused by the addition of extracellular Ca2+ were inhibited by bractelactone in FMLP-activated cells. In addition, bractelactone did not alter the phosphorylation of p38 MAPK, ERK, JNK, or AKT or the concentration of cAMP. These results suggest that bractelactone selectively inhibits store-operated calcium entry (SOCE). In agreement with this concept, bractelactone suppressed sustained [Ca2+]i changes in thapsigargin-activated neutrophils. Furthermore, bractelactone did not alter FMLP-induced formation of inositol 1,4,5-triphosphate. Taken together, our results demonstrate that the anti-inflammatory effects of bractelactone, an active ingredient of F. bracteolatum, in human neutrophils are through the selective inhibition of SOCE.

KW - Bractelactone

KW - Calcium

KW - Elastase

KW - Fissistigma bracteolatum

KW - Neutrophils

KW - Superoxide anion

KW - Bractelactone

KW - Calcium

KW - Elastase

KW - Fissistigma bracteolatum

KW - Neutrophils

KW - Superoxide anion

UR - http://www.scopus.com/inward/record.url?scp=84871875351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871875351&partnerID=8YFLogxK

U2 - 10.1016/j.taap.2012.11.021

DO - 10.1016/j.taap.2012.11.021

M3 - Article

C2 - 23201462

AN - SCOPUS:84871875351

VL - 266

SP - 399

EP - 407

JO - Toxicology and Applied Pharmacology

JF - Toxicology and Applied Pharmacology

SN - 0041-008X

IS - 3

ER -